argenx SE (NASDAQ:ARGX) delivered a clearly positive headline result from the Phase 3 ALKIVIA trial. VYVGART Hytrulo produced a 15.4-point mean advantage over placebo on the Total Improvement Score, or TIS, at Week 52 in the combined immune-mediated necrotizing myopathy and dermatomyositis population. The difference was statistically significant, with a p-value of 0.0011.
The result is especially important in immune-mediated necrotizing myopathy, or IMNM, where VYVGART Hytrulo became the first therapy to demonstrate statistically significant improvement in a Phase 3 trial. Yet argenx SE (NASDAQ:ARGX) did not deliver a uniform victory. The smaller dermatomyositis subgroup showed a 14.5-point numerical advantage, but the result was not statistically significant.
BULL CASE: AN ESTABLISHED DRUG CAN ENTER AN UNDERSERVED INDICATION
For argenx SE (NASDAQ:ARGX), the strongest part of the readout is the IMNM result. The subgroup recorded a 14.8-point treatment difference and a p-value of 0.0048. IMNM has no approved treatment, giving VYVGART Hytrulo a potential path into a market with substantial unmet need.
This is not an untested molecule. argenx SE (NASDAQ:ARGX) is expanding a drug that is already commercialized, supported by an established safety profile and a growing prescriber base. That can reduce development and launch risk compared with building a new franchise from scratch. VYVGART generated $1.516 billion of global product net sales in the second quarter, giving the company a commercial platform for another indication.
argenx SE (NASDAQ:ARGX) also reported that improvement appeared by Week 4 and continued through Week 52 despite protocol-directed steroid tapering. The company reported that all six score components favored treatment and that skin-disease activity improved, although detailed component-level statistics were not disclosed.
BEAR CASE: DERMATOMYOSITIS REPRESENTS THE LARGER PATIENT POPULATION
The bear case for argenx SE (NASDAQ:ARGX) centers on dermatomyositis. The company estimates roughly 40,000 U.S. patients with dermatomyositis, compared with about 20,000 with IMNM. A statistically inconclusive result in the larger patient population could influence the eventual label, addressable market, physician confidence, or demands for additional evidence.
The numerical effect in dermatomyositis was close to the IMNM result, so the miss may reflect the smaller sample rather than a lack of activity. Still, argenx SE (NASDAQ:ARGX) has not yet released the details needed to judge that question fully. Detailed subgroup enrollment, confidence intervals, response distributions, missing-data handling, the multiplicity plan, steroid-taper outcomes, and adverse-event rates will matter when the full dataset is presented.
FEWER HEDGE FUNDS HELD ARGX BEFORE THE READOUT
The filings available so far reflect positions held before the ALKIVIA readout was announced. Insider Monkey’s first-quarter database showed 42 hedge funds holding argenx SE (NASDAQ:ARGX) at the end of March 2026, down from 48 funds three months earlier.
CONCLUSION
The preliminary conclusion is straightforward. ALKIVIA strengthens the VYVGART franchise and creates a credible opportunity in an indication with no approved therapy. The dermatomyositis miss does not erase that success, but it leaves an important commercial and regulatory question unresolved. This was a meaningful win, not yet a uniform victory across myositis subtypes.
While we acknowledge the risk and potential of ARGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: ConocoPhillips (COP): Wall Street Sees More Upside Despite Leadership Shakeup and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center